Key Highlights from the Presentation:

• Nine of 20 patients with LM primary breast cancer were treated and evaluable through five dose escalation cohorts, with the maximum tolerated dose yet to be reached
• Primary breast cancer biomarker status across the 9 patients were:
  • ER positive/HER2 negative: n=3
  • HER2 positive: n=2
  • Triple negative: n=4
• Patients received a single intrathecal dose of Rhenium (186Re) Obisbemeda, ranging from 6.6 to 66.14 mCi of radiation
• Only one dose-limiting toxicity (thrombocytopenia) was reported (Cohort 5)
• A linear increase in absorbed dose was observed from Cohorts 1 through 5, with an average absorbed dose of 253 Gy to the cranial subarachnoid space in Cohort 5
• Circulating tumor cell (CTC) and radiographic (MRI) response data were available for 8 of the 9 breast cancer patients with LM, and clinical response data were available for 7 of the 9 patients
  • Best response rates (response only) were:
    • CTC: 88% (7/8)
    • MRI imaging: 25% (2/8)
    • Clinical: 29% (2/7)
  • Clinical benefit rates (response and stable disease) were:
    • CTC: 100% (8/8)
    • MRI imaging: 75% (6/8)
    • Clinical: 71 % (5/7)
• Median overall survival for 9 breast cancer patients was 9 months, with 2 patients surviving beyond 600 days post-treatment